Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Influenza Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Agreement
Details : ImplaVax®-enabled vaccination products leverage Enesi’s innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies, and are applicable across all vaccine formats such as recombinant H7N9 pandemic influenza vaccine.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 19, 2021
Lead Product(s) : Influenza Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : PRRSV vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : The Pirbright Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study investigating potential of solid-dose vaccine for porcine reproductive and respiratory syndrome virus (PRRSV) conducted in collaboration with The Pirbright Institute.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 29, 2020
Lead Product(s) : PRRSV vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : The Pirbright Institute
Deal Size : Inapplicable
Deal Type : Inapplicable